- Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and field option payments, plus tiered royalties on future sales -Deal underscores the commercial potential of Alumis' ESK-001 and leverages Kaken's regional capabilities and expertise in novel dermatology treatments -Kaken has the option to license ESK-001 for further clinical development and commercialization in rheumatological and gastrointestinal diseases SOUTH SAN FRANCISCO, Calif. and BUNKYO-KU, Tokyo, March 25, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmac

– Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated; Phase 3 ONWARD program data readout now expected 1Q 2026 – – Presented Phase 1 clinical data at ACTRIMS 2025 demonstrating first-in-class oral TYK2 inhibitor A-005 has ability to cross blood-brain barrier and was well tolerated; Phase 2 in MS to begin 2H 2025 – – Announced merger agreement with ACELYRIN to create combined company with differentiated late-stage portfolio of therapies and strong balance sheet; expected to close 2Q 2025 – SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEW

SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will participate in a fireside chat at Leerink's 2025 Global Healthcare Conference on Tuesday, March 11, 2025 at 10:40 am ET. A live webcast will be available on the Alumis website in the "Investors" section under the "Events" page. About Alumis Alumis is a clinical-stage biopharmaceutical company developing oral

ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and systemic lupusPhase 2 OLE data of ESK-001 at 40 mg BID demonstrated sustained or increasing clinical responses through week 52 on PASI 90, PASI 100, and sPGA 0ESK-001 was generally well-tolerated at one year, with no new safety findingsData further support ESK-001's potential to offer a highly differentiated and best-in-class treatment option for people with moderate-to-severe plaque psoriasisPhase 3 ONWARD program ongoing with topline data expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., March 08, 2025 (GLOBE NEWSWIRE) -- Alumis I

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN) and Alumis Inc. (NASDAQ:ALMS) today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases. Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, "Alumis and ACELYRIN together will advance exciting breakthroughs for patients and drive long-term value for stockholders through the creation of a leading clinical stage biopharma company in immu

SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS) ("Alumis") and ACELYRIN, INC. (NASDAQ:SLRN) ("ACELYRIN") today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases. Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, "Alumis and ACELYRIN together will advance exciting breakthroughs for patients and drive long-term value for stockholders through the creation of a leading clinical stage biopharma company in immune-mediated diseases. The combined company will have a significantly strengthened financial posi

All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, after due consideration in consultation with its independent financial and legal advisors, its Board of Directors determined that the unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, is not reasonably expected to result in a superior proposal to the planned merger with Alumis Inc. (NASD

– Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension (OLE) study in adults with moderate-to-severe plaque psoriasis – – Additional Phase 2 e-poster presentations to describe patient-reported outcomes, disease biomarker activity and pharmacokinetic data of ESK-001 in psoriasis patients – – Phase 3 ONWARD program topline data now expected in Q1 2026 – SOUTH SAN FRANCISCO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS) ("Alumis" or the "Company"), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS) ("Alumis" or the "Company"), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced the Company will give two data presentations on A-005, a potent, selective, central nervous system (CNS) penetrant tyrosine kinase 2 (TYK2) inhibitor, on Friday, February 28, 2025, at the 10th Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025. "These data demonstrate that A-005 potently inhibits TYK2-specific

LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, to acquire all of the outstanding shares of ACELYRIN for $3.00 per share in cash, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of ACELYRIN's development programs or intellectual property. On February 6, 2025, ACELYRIN announced an

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4/A - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN's lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical readouts for highly differentiated late-stage portfolio Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis Combined company wi

S-4/A - ALUMIS INC. (0001847367) (Filer)

S-4 - ALUMIS INC. (0001847367) (Filer)

8-K - ALUMIS INC. (0001847367) (Filer)

S-8 - ALUMIS INC. (0001847367) (Filer)

10-K - ALUMIS INC. (0001847367) (Filer)

8-K - ALUMIS INC. (0001847367) (Filer)

8-K - ALUMIS INC. (0001847367) (Filer)

8-K - ALUMIS INC. (0001847367) (Filer)

8-K - ALUMIS INC. (0001847367) (Filer)

8-K - ALUMIS INC. (0001847367) (Filer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

Oppenheimer initiated coverage of Alumis with a rating of Outperform and set a new price target of $32.00

Robert W. Baird initiated coverage of Alumis with a rating of Outperform and set a new price target of $25.00

H.C. Wainwright initiated coverage of Alumis with a rating of Buy and set a new price target of $30.00

Cantor Fitzgerald initiated coverage of Alumis with a rating of Overweight

Leerink Partners initiated coverage of Alumis with a rating of Outperform and set a new price target of $29.00

Guggenheim initiated coverage of Alumis with a rating of Buy and set a new price target of $32.00

Morgan Stanley initiated coverage of Alumis with a rating of Overweight and set a new price target of $36.00